R-Tech Ueno: Announcement of Commercial Availability of RESCULA® Eye Drops in the U.S. Market by EON

VIEWS: 6 PAGES: 2

TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (hereinafter referred to as "Sucampo") announced that RESCULA® Eye Drops had been launched in the U.S. market. (See Sucampo's press release dated February 19, 2013.) RESCULA® Eye Drops may be used as a first-line agent or concomitantly with other topical ophthalmic drug products with ocular hypotensive effect for treatment of open-angle glaucoma, which is the most common form of glaucoma, or ocular hypertension. RES a style='font-

More Info
To top